XBiotech (Nasdaq:XBIT) - Aandelenkoers, Nieuws & Analyse

XBIT Overzicht aandelen

XBiotech Inc., een biofarmaceutisch bedrijf, ontdekt, ontwikkelt en verkoopt True Human monoklonale antilichamen voor de behandeling van verschillende ziekten.

Over het bedrijf

XBIT fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

Risicoanalyse

De winst is de afgelopen 5 jaar met 65.3% per jaar gedaald

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Volatiele aandelenkoers in de afgelopen 3 maanden

XBiotech Inc. Concurrenten

Solid Biosciences

NasdaqGS:SLDB

US$220.4m

uniQure

NasdaqGS:QURE

US$318.2m

Leap Therapeutics

NasdaqCM:LPTX

US$137.8m

Cibus

NasdaqCM:CBUS

US$113.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor XBiotech
Historische aandelenkoersen
Huidige aandelenkoers	US$7.17
52 Week Hoogtepunt	US$9.96
52 Week Laag	US$3.51
Bèta	1.41
11 maand verandering	-0.55%
3 maanden verandering	-3.50%
1 Jaar Verandering	79.25%
33 jaar verandering	-53.23%
5 jaar verandering	-32.36%
Verandering sinds IPO	-68.43%

Recent nieuws en updates

Recent updates

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

Aug 30

XBiotech: Several Shots On Goal In Big Target Market Indications

May 24

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

May 13

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

Feb 09

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

Oct 25

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

Jun 16

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

May 11

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

Mar 18

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

Jan 08

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

Nov 19

Rendement voor aandeelhouders

	XBIT	US Biotechs	US Markt
7D	-5.3%	-1.3%	-0.9%
1Y	79.3%	27.9%	38.9%

Rendement versus industrie: XBIT overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 22.1 % opleverde.

Rendement versus markt: XBIT overtrof de US markt, die het afgelopen jaar een rendement opleverde van 34.1 %.

Prijsvolatiliteit

Is XBIT's price volatile compared to industry and market?
XBIT volatility
XBIT Average Weekly Movement	10.9%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.0%

Stabiele aandelenkoers: De aandelenkoers van XBIT is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 12% ) van XBIT is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2005	94	John Simard	www.xbiotech.com

XBiotech Inc, een biofarmaceutisch bedrijf, ontdekt, ontwikkelt en verkoopt True Human monoklonale antilichamen voor de behandeling van verschillende ziekten. Het bedrijf richt zich op het ontwikkelen van een pijplijn van productkandidaten gericht op zowel ontstekings- als infectieziekten. Het ontwikkelt ook interleukine-1 alfa-therapieën voor de behandeling van verschillende medische aandoeningen, zoals kanker, beroerte, hartaanval of artritis; en medieert weefselafbraak, angiogenese, de vorming van bloedstolsels, malaise, spieratrofie en ontsteking.

XBiotech Inc. Samenvatting

Hoe verhouden de winst en inkomsten van XBiotech zich tot de beurswaarde?
XBIT fundamentele statistieken
Marktkapitalisatie	US$218.42m
Inkomsten(TTM)	-US$35.01m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-6.2x

Koers/Winstverhouding

Is XBIT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
XBIT resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$35.01m
Inkomsten	-US$35.01m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.15
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	5.1%

Hoe presteerde XBIT op de lange termijn?

Bekijk historische prestaties en vergelijking

XBIT Overzicht aandelen

Beloningen

Risicoanalyse

XBiotech Inc. Concurrenten

NasdaqGS:SLDB

US$220.4m

NasdaqGS:QURE

US$318.2m

NasdaqCM:LPTX

US$137.8m

NasdaqCM:CBUS

US$113.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech: Several Shots On Goal In Big Target Market Indications

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

XBiotech Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

Recent updates

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech: Several Shots On Goal In Big Target Market Indications

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

XBiotech Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

XBiotech Inc. announced that it expects to receive $10 million in funding

Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke

Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

First half 2023 earnings released: US$0.41 loss per share (vs US$0.56 loss in 1H 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$1.08 loss per share (vs US$0.58 loss in FY 2021)

XBiotech Inc. Announces Executive Changes

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

Insufficient new directors

Third quarter 2022 earnings released: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

XBiotech Inc. Announces First Patient Enrolled into the French National Cancer Institute Sponsored Phase I/Ii/Iii Clinical Study for Natrunix™ Therapy for Colorectal Cancer

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.17 loss in 2Q 2021)

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 2000 Dynamic Index

XBiotech Announces Successful Completion of Phase I Portion of Pancreatic Cancer Study

XBiotech Inc., Annual General Meeting, Jun 22, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Insufficient new directors

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.087 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 2Q 2020)

Board Member exercised options to buy US$452k worth of stock.

XBiotech Inc. Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer

Founder exercised options to buy US$9.8m worth of stock.

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

New 90-day high: US$19.83

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

New 90-day low: US$16.72

Independent Director notifies of intention to sell stock

Xbiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-Covid-19 Therapeutic Cocktail

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections

New 90-day high - US$19.95

New 90-day high - US$19.57

New 90-day high - US$16.08

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 3000 Growth Index

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

XBiotech Inc. Samenvatting

0.0x

-6.2x

Inkomsten en omzet